Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
B01AC24
|
| gptkbp:CASNumber |
gptkb:658066-35-4
|
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| gptkbp:hasMolecularFormula |
C23H28F2N6O4S
|
| gptkbp:hasSMILES |
CC1=NC2=C(N1)C(=NC=N2)N3CCN(CC3)C(=O)COC4=CC=CC=C4C5=CC(=C(C=C5)F)S(=O)(=O)N
|
| gptkbp:hasUNII |
8S0S5V38KA
|
| https://www.w3.org/2000/01/rdf-schema#label |
658066-35-4
|
| gptkbp:marketedAs |
gptkb:Brilinta
|
| gptkbp:mechanismOfAction |
P2Y12 receptor antagonist
|
| gptkbp:molecularWeight |
522.57 g/mol
|
| gptkbp:name |
gptkb:Ticagrelor
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL573
DB08816 9871419 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:usedFor |
gptkb:acute_coronary_syndrome
prevention of thrombotic events antiplatelet drug |
| gptkbp:bfsParent |
gptkb:Fluopyram
|
| gptkbp:bfsLayer |
7
|